GLP-1 Weight Loss Medication Cost in Poland 2026 — Budget Impact Guide

Quick Answer

GLP-1 medications (Ozempic, Wegovy, Mounjaro, Saxenda) cost in Poland in 2026 approximately PLN 700-1500 per month (roughly €170-€350) when paid out-of-pocket without reimbursement. Annual cost ranges from PLN 8 400 to PLN 18 000 (around €2 000-€4 200) — comparable to a yearly premium for private healthcare for a small family.

NFZ (Polish public health system) reimbursement in Poland currently covers only patients with diagnosed type 2 diabetes (specific semaglutide doses meeting clinical criteria). Obesity, overweight, or cosmetic weight loss are not currently grounds for reimbursement — patient pays 100% of retail price.

This is a financial guide, not medical advice. Any decision about taking GLP-1 medications must be made with your treating physician (diabetologist, endocrinologist, or GP). This article focuses on what costs to expect and how to plan a healthcare budget if treatment is initiated.

Who this is for

• Expats and Polish residents whose doctors have suggested considering GLP-1 (type 2 diabetes, obesity with BMI > 30 with comorbidities).
• Self-pay patients comparing annual medication cost with alternatives (dietitian, personal trainer, bariatric surgery, structured nutrition).
• Households planning a healthcare budget — medications, private insurance, monitoring tests.
• Financial advisors of clients introducing a recurring PLN 800-1500/month expense.

In Freenance, we see in user data that introducing a recurring PLN 1000+ monthly expense in a budget of PLN 6 000-8 000 net often requires restructuring other categories. This is a substantial financial decision, not only a health decision.

Key 2026 numbers

• Ozempic 0.25 mg (4 pens): approx. PLN 500-700 per monthly pen (€115-160)
• Ozempic 0.5 mg / 1 mg: approx. PLN 700-900/month (€160-210)
• Wegovy (0.25 to 2.4 mg): approx. PLN 1100-1500/month (€255-350)
• Mounjaro (tirzepatide, 2.5-15 mg): approx. PLN 1000-1500/month (€230-350)
• Saxenda (liraglutide): approx. PLN 800-1100/month (€185-255)
• NFZ reimbursement (type 2 diabetes only): reduces cost to ~PLN 30-150/month, only in specific clinical indications
• Annual cost without reimbursement: PLN 8 400-18 000 (€2 000-€4 200)
• Average treatment duration: 12-24 months per clinical studies; many patients discontinue due to cost
• Effectiveness (weight loss): 10-20% of body weight per Wegovy/Mounjaro registration trials

Prices are indicative as of early 2026 and can vary by pharmacy, dose, parallel importer, and current availability. Always verify current prices at pharmacy before starting treatment.

What GLP-1 medications are

GLP-1 (Glucagon-Like Peptide-1) is a class of drugs mimicking the natural intestinal hormone GLP-1 secreted after meals. Mechanism:

• Slow gastric emptying — sustained satiety
• Stimulate glucose-dependent insulin secretion — help in type 2 diabetes
• Suppress glucagon secretion (the hormone that raises blood sugar)
• Act on appetite centers in the brain — reduce hunger

Main preparations available on the Polish market:

• Semaglutide (Ozempic — diabetes, Wegovy — obesity)
• Liraglutide (Saxenda — obesity, Victoza — diabetes)
• Tirzepatide (Mounjaro — dual GLP-1 + GIP agonist)

In clinical trials, tirzepatide (Mounjaro) shows higher average weight reduction than semaglutide, but availability and price in Poland in 2026 remain variable.

2026 pricing detail

Approximate retail prices in Polish pharmacies (as of early 2026 — verify with pharmacist):

Ozempic (semaglutide):

• 0.25 mg pen — starting dose, ~PLN 500-700/month
• 0.5 mg pen — most commonly prescribed maintenance dose, ~PLN 700-900/month
• 1.0 mg pen — higher diabetes dose, ~PLN 800-950/month

Wegovy (semaglutide for obesity):

• 0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg (monthly escalation)
• 1.7 mg / 2.4 mg target dose: ~PLN 1300-1500/month
• Wegovy availability in Poland has been intermittent — check current stock

Mounjaro (tirzepatide):

• 2.5-15 mg (4-week escalation)
• ~PLN 1000-1500/month, dose-dependent

Saxenda (liraglutide):

• 3 mg/day, daily injection (Ozempic / Wegovy weekly)
• ~PLN 800-1100/month

NFZ reimbursement — eligibility

In Poland, GLP-1 reimbursement covers exclusively diabetes indications:

• Type 2 diabetes with HbA1c > 7.5% despite maximum metformin dose (and additional clinical criteria)
• Patient must have a diagnosis per PTD/NFZ guidelines
• Reimbursement-marked prescription (e.g. 30%, 50%, fixed fee) — issued by diabetologist or certified GP

What is not reimbursed:

• Obesity (even BMI > 30) without diabetes
• Overweight with comorbidities (hypertension, dyslipidemia, sleep apnea) — full payment still applies
• Cosmetic / aesthetic weight loss

The NFZ reimbursement list is updated every 2 months — check the current Ministry of Health version. This may change during 2026 — some EU countries are expanding coverage to BMI > 35 patients.

Pharmacies and parallel imports

Bricks-and-mortar pharmacies in Poland: prices broadly similar, but PLN 50-100/month differences are common. Compare 2-3 pharmacies.

Online pharmacies (legal in Poland for OTC, prescription medications dispensed via in-store pickup): prices often slightly lower, but availability not always faster.

Parallel imports — some packages come from other EU countries (Germany, France). Price may be 10-20% lower; package has foreign-language leaflet (pharmacy adds Polish version).

Compounding pharmacies (US) — Poland has no legal mechanism for "compounded" GLP-1. Ordering from US without a Polish prescription may be illegal under individual import regulations. Not recommended — consult a lawyer before any cross-border purchases.

Annual cost vs alternatives

Annual GLP-1 cost without reimbursement: PLN 8 400-18 000 (€2 000-€4 200).

Comparison with other weight management approaches in Poland in 2026:

• Clinical dietitian: PLN 200-400/visit, 6-12 visits/year = PLN 1 200-4 800/year
• Personal trainer: PLN 100-200/session, 2x/week = PLN 10 400-20 800/year
• Group fitness (gym, crossfit, classes): monthly pass PLN 150-400 = PLN 1 800-4 800/year
• Bariatric surgery: sleeve gastrectomy private ~PLN 25 000-40 000 one-time, gastric bypass higher. NFZ covers in defined indications (BMI > 40 or > 35 + comorbidities)
• Structured meal delivery: PLN 1 600-3 000/month = PLN 19 200-36 000/year

GLP-1 doesn't replace diet and exercise — clinical studies show best outcomes when pharmacotherapy is combined with lifestyle modification.

Impact on household budget

A recurring PLN 800-1500/month expense in a Polish household budget is significant. Against 2026 median net wages (~PLN 5 500/month) — that's 15-25% of monthly income on a single medication.

Financing strategies:

• Dedicated "health/medications" sub-account — automated transfer of PLN 1 000-1 500/month to a separate savings account that funds the medication + monitoring tests
• Restructure other expenses — analyzing discretionary outflows (dining out, subscriptions, unused gym memberships) often reveals PLN 1 000-2 000/month to redirect
• Private health insurance with prescription benefit — some packages offer partial drug reimbursement, but GLP-1 is rarely covered
• Consult a dietitian before starting GLP-1 — sometimes structured lifestyle changes alone produce 5-10% weight reduction, and pharmacotherapy may not be necessary (this is a medical decision)

In Freenance, you can create a dedicated "health/medications" category and track how a new expense affects other budget areas — without maintaining a separate spreadsheet.

Health ROI — full picture

The medication isn't only an expense — it can also reduce other costs:

• Lower cost of antihypertensives / statins / antidiabetics — patients with obesity often take 3-5 other medications. Weight reduction of 10-20% may allow lower doses or discontinuation of some (medical decision)
• Fewer specialist visits — better diabetes/hypertension control means less frequent follow-up
• Reduced hospitalization risk — indirect savings (work absence, family costs)
• Quality of life — hard to price in PLN, but real

Risk of relapse after discontinuation: Studies show that ~70% of lost weight returns within 12 months after stopping GLP-1. This means treatment is often long-term (years), not a 6-month course. Discuss the planned treatment horizon with your physician — it affects multi-year financial planning.

Insurance coverage in Poland

NFZ: Type 2 diabetes only, with specific indications.

Private health insurance (PZU Zdrowie, Medicover, LUX MED, Enel-Med): Standard packages typically do not cover GLP-1. Premium packages with "drug" add-ons may offer partial reimbursement (10-30% of cost), but rarely cover GLP-1 explicitly — verify with insurance agent.

International expat health insurance (Cigna, Allianz Care, IMG): Some plans cover GLP-1 with cosmetic-use exclusions.

Employer health benefits — some corporate packages add a "medication budget" of PLN 500-1 000/year. Ask HR.

Side effects and monitoring costs

GLP-1 medications are not benign — they have known side effects and require monitoring.

Common side effects (per labels):

• Nausea, vomiting (especially during dose escalation)
• Diarrhea / constipation
• Headache
• Fatigue
• Acid reflux

Less common but significant:

• Pancreatitis
• Gallbladder disease
• Diabetic retinopathy changes
• Reported in studies: potential association with thyroid tumors (rare)

Monitoring costs (2026 estimates):

• Specialist visits (diabetologist/endocrinologist): PLN 200-400 × 2-4/year = PLN 400-1 600/year
• Blood work (HbA1c, glucose, lipid panel, liver function): PLN 150-300 × 2/year = PLN 300-600/year
• Abdominal ultrasound (gallbladder check): PLN 150-300 once/year
• Additional consultations if side effects occur

Total monitoring overhead: PLN 700-2 500/year on top of the medication cost.

Budget strategy

1. Discuss treatment horizon with your physician. 6 months or 5 years? Determines the scale of the expense.
2. Create a dedicated "health/medications" line item — minimum sum of medication cost + tests + visits.
3. Check reimbursement eligibility — do you meet criteria? Consult GP or diabetologist.
4. Compare 3 pharmacies — PLN 100-200/month differences mean PLN 1 200-2 400/year.
5. Consider parallel approaches — dietitian + group exercise can produce comparable effects at lower cost. Individual medical decision.
6. Negotiate with employer — corporate roles sometimes cover medications under wellness benefits.
7. Financial Plan B — what if you lose income? Long-term GLP-1 spend deserves contingency planning.

Common mistakes

• Buying at the first pharmacy without comparison — price differences are real
• Ordering from US / illegal sources — legal risk, counterfeit risk
• No budget for monitoring tests — unmonitored treatment = health risk
• Ignoring side effects — paying for medication your body doesn't tolerate is wasteful
• Short treatment without exit plan — without lifestyle change, ~70% of weight returns post-discontinuation
• Skipping alternatives — some patients achieve comparable results from structured nutrition and exercise alone

30/60/90 action plan

Days 1-30

• Consultation with GP / diabetologist / endocrinologist
• Baseline tests (HbA1c, lipid panel, liver function, abdominal ultrasound)
• Verify reimbursement criteria (if type 2 diabetes)
• Compare prices at 3 pharmacies

Days 31-60

• Decision in agreement with physician
• Create "health/medications" budget category
• Restructure other expenses if needed
• Dose escalation per physician guidance (typically every 4 weeks)

Days 61-90

• First check-up: efficacy, side effects, possible dose adjustment
• Annual budget update — does the medication fit the plan?
• Dietitian consultation (improves efficacy, optimizes long-term cost)
• Assess: continue, modify, or switch to alternative

FAQ

How much does Ozempic cost in Poland in 2026?

Approximately PLN 500-900 (€115-€210) per monthly pen (4 injections), depending on dose (0.25 / 0.5 / 1 mg) and pharmacy. The 0.5 mg dose, most commonly prescribed for type 2 diabetes, costs about PLN 700-900/month without reimbursement. With NFZ reimbursement (type 2 diabetes, criteria met) — typically PLN 30-150/month.

Does NFZ cover Ozempic for obesity?

No. NFZ reimbursement of GLP-1 medications currently covers only type 2 diabetes meeting clinical criteria (HbA1c, metformin failure). Obesity without diabetes means full out-of-pocket payment. The reimbursement list is updated every 2 months — this may change.

What's the annual cost of GLP-1 therapy?

Without reimbursement — PLN 8 400-18 000 (€2 000-€4 200) per year for the medication alone, depending on preparation and dose. Add PLN 700-2 500/year for monitoring visits and labs. Total: budget PLN 10 000-20 000/year for the healthcare line item.

How long do you need to take GLP-1?

Your physician decides. Clinical studies show that discontinuation after 6-12 months commonly results in ~70% of lost weight returning within the next year. Many patients continue 2-5 years or longer. This affects multi-year financial planning — discuss treatment horizon with your physician.

Are there cheaper alternatives?

Yes — clinical dietitian + nutrition plan + regular exercise costs PLN 2 000-7 000/year and produces 5-10% weight reduction in some patients without medication. Bariatric surgery is PLN 25-40k one-time privately or free under NFZ with eligibility. Choosing an alternative is a medical decision — consult your physician.

Can I buy Ozempic from the US where it's cheaper?

Individual import of prescription drugs into Poland is governed by strict pharmaceutical regulations. Compounded GLP-1 from US lacks legal pathway into Poland. Consult a lawyer and pharmacist before any cross-border purchases — there's both legal risk and counterfeit risk.

How much for a dietitian instead of Ozempic?

Clinical dietitian in Poland in 2026 charges PLN 200-400 per visit. Standard cooperation: 6-12 visits annually + nutrition plan = PLN 1 200-4 800/year. That's 5-15× cheaper than GLP-1, but average effectiveness in the literature is lower — ~5-7% weight reduction vs 10-20% with GLP-1. Choice is between you and your physician.

Are GLP-1 medications safe for everyone?

No. Contraindications exist (history of pancreatitis, certain thyroid cancers, pregnancy). Side effects (nausea, diarrhea, headache) are common, and rarely serious complications can occur. Medical consultation and monitoring required. This article is not medical advice.

Will private insurance cover it?

Standard private healthcare packages in Poland (PZU Zdrowie, Medicover, LUX MED, Enel-Med) most often do not cover prescription medications. Premium packages with drug budget rarely cover GLP-1. Verify with your insurance agent before purchase.

Does GLP-1 affect other healthcare expenses?

Yes — losing 10-20% of body weight often allows lower doses or discontinuation of antihypertensives, statins, or oral antidiabetics (medical decision). This may reduce total treatment cost by several hundred PLN annually. On the other hand, monitoring visits and labs add PLN 700-2 500/year.

Should I wait for obesity coverage?

In several EU countries (UK partially, some German sickness funds), GLP-1 coverage for obesity is being expanded. In Poland, no concrete announcement of broad obesity coverage as of early 2026. Make treatment decisions on current circumstances, not future promises — consult your treating physician.

Why not just a spreadsheet

Adding a recurring PLN 1000+/month expense requires reviewing the entire budget — what's left for emergency fund, other health needs, investments. A spreadsheet shows you a table but won't automatically recalculate consequences across all budget categories or sync income and expenses with your bank account. In Freenance, the "health/medications" category sits next to all others in a single dashboard with automatic updates.

Disclaimer

This is not medical or financial advice. Decisions about GLP-1 medications must be made exclusively by your treating physician (diabetologist, endocrinologist, or trained GP). Prices may vary by pharmacy, purchase date, parallel importer, and current availability — always verify current prices with your pharmacist. NFZ reimbursement is subject to changes via Ministry of Health reimbursement lists. Consult a financial advisor on healthcare budget structure before introducing a recurring expense of this magnitude.